Phase II Study of WT1 126-134 Peptide Vaccination in Combination With Adjuvants GM-CSF and KLH in Carcinomas
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Clinical efficacy
Ulrich Keilholz, MD
Principal Investigator
Charité CBF
Germany: Federal Institute for Drugs and Medical Devices
HaemaCBFWT104
NCT00153608
April 2004
Name | Location |
---|